The salt is crystalline or amorphous phosphate, or crystalline or amorphous oxalate. Particularly, a crystal form B of the phosphate of the present invention has high crystallinity, low hygroscopicity and good stability, and the crystal form B of the phosphate is good in oral bioavailability, good in tolerance after long-term administration, difficult to induce hypoglycemia and good in inhibition effect on serum DPPIV."/>
公开/公告号US11046701B2
专利类型
公开/公告日2021-06-29
原文格式PDF
申请/专利号US201816626220
申请日2018-05-29
分类号C07D487/04;A61P3/10;
国家 US
入库时间 2022-08-24 19:39:20